332099-11-3

Basic information

• Product Name: 2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid
• Synonyms: 2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid
• CAS NO: 332099-11-3
• Molecular Formula: C7H4BrNO3
• Molecular Weight: 230
• Mol File: 332099-11-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 2.028
• CAS DataBase Reference: 2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid(332099-11-3)
• EPA Substance Registry System: 2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid(332099-11-3)

Safety Data

• Hazardous Substances Data: 332099-11-3(Hazardous Substances Data)

Usage

General Description

2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid is a chemical compound with a molecular formula C7H4BrNO3. It is a pyrrole derivative with a furo[3,2-b]pyrrole core structure and a carboxylic acid functional group. 2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid is commonly used in organic synthesis, medicinal chemistry, and drug development as a building block for the synthesis of various pharmaceutical compounds. It has been studied for its potential biological activities, including as an antiviral and anti-inflammatory agent. Additionally, it has also been used in the development of novel materials and as a reagent in chemical research.

Relevant articles and documents

The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors

The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.

Use of glycogen phosphorylase inhibitors

The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.